(Q37850996)

24 August 2017

1 reference

title

Adrenocortical carcinoma: a clinician's update (English)

1 reference

24 August 2017

main subject

adrenocortical carcinoma

1 reference

Rossella Libé

2

0 references

author name string

Martin Fassnacht

series ordinal

1

1 reference

24 August 2017

Matthias Kroiss

series ordinal

3

1 reference

24 August 2017

Bruno Allolio

series ordinal

4

1 reference

24 August 2017

publication date

8 March 2011

1 reference

Nature Reviews Endocrinology

24 August 2017

published in

1 reference

24 August 2017

volume

7

1 reference

24 August 2017

issue

6

1 reference

24 August 2017

page(s)

323-335

1 reference

Management of the clinically inapparent adrenal mass ("incidentaloma")

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Clinical review: Prevalence and incidence of endocrine and metabolic disorders in the United States: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinoma -- improving patient care by establishing new structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenal cortical carcinoma. Clinical features of 138 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Genotyping of Adrenocortical Tumors: Very Frequent Deletions of the MEN1 Locus in 11q13 and of a 1-Centimorgan Region in 2p16

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Parental imprinting of the mouse insulin-like growth factor II gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

The proteus syndrome. Partial gigantism of the hands and/or feet, nevi, hemihypertrophy, subcutaneous tumors, macrocephaly or other skull anomalies and possible accelerated growth and visceral affections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Tumor formation by genetic mutations in the components of the Wnt signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Minireview: transcriptional regulation of adrenocortical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

High Diagnostic and Prognostic Value of Steroidogenic Factor-1 Expression in Adrenal Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Pre-B-cell transcription factor 1 and steroidogenic factor 1 synergistically regulate adrenocortical growth and steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Inhibition of adrenocortical carcinoma cell proliferation by steroidogenic factor-1 inverse agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Differential effects of transforming growth factor type beta on the growth and function of adrenocortical cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Transforming growth factor beta 1: an autocrine regulator of adrenocortical steroidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Angiogenesis in human normal and pathologic adrenal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Epidermal growth factor receptor in adrenocortical tumors: analysis of gene sequence, protein expression and correlation with clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Multiple primary cancers in families with Li-Fraumeni syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

p53 mutations in sporadic adrenocortical tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Molecular markers and the pathogenesis of adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

ACTH-receptor expression, regulation and role in adrenocortial tumor formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

The Italian Registry for Adrenal Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients. The ACC Italian Registry Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinoma: surgical progress or status quo?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

21 January 2018

Adrenocortical carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenal cortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn's syndrome with an ominous clinical course.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical Carcinoma and Hypoglycemia: Evidence for Production of Nonsuppressible Insulin-Like Activity by the Tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Clinical review: Adrenocortical carcinoma: clinical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical cancer: pathophysiology and clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Clinical management of adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

The optimal imaging of adrenal tumours: a comparison of different methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Comparison of delayed enhanced CT and chemical shift MR for evaluating hyperattenuating incidental adrenal masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

[123 I]Iodometomidate for molecular imaging of adrenocortical cytochrome P450 family 11B enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

11C-metomidate PET imaging of adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

[11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Immunohistochemistry of a proliferation marker Ki67/MIB1 in adrenocortical carcinomas: Ki67/MIB1 labeling index is a predictor for recurrence of adrenocortical carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Needle biopsy of incidentally discovered adrenal masses is rarely informative and potentially hazardous

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Management of patients with adrenal cancer: recommendations of an international consensus conference.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Trends in adrenalectomy: a recent national review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adjuvant mitotane treatment for adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adjuvant mitotane for adrenocortical cancer--a recurring controversy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adjuvant mitotane for adrenocortical cancer--working through uncertainty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adjuvant therapy in patients with adrenocortical carcinoma: a position of an international panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Radiotherapy in adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Radiofrequency thermal ablation of hepatic metastases of adrenocortical cancer--a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Streptozocin and o,p'DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing's syndrome and dose-response relationship in normal subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

New mechanisms of adrenostatic compounds in a human adrenocortical cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Mifepristone (RU 486) in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Merits and pitfalls of mifepristone in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Treatment of advanced adrenocortical carcinoma with erlotinib plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

New targets and therapeutic approaches for endocrine malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinoma. Clinical outcome at the end of the 20th century

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Glucose transporter GLUT1 expression is an stage-independent predictor of clinical outcome in adrenocortical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

What is the best approach to an apparently nonmetastatic adrenocortical carcinoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical Carcinoma: Clinical, Morphologic, and Molecular Characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Fine-needle aspiration cytology of adrenal masses in noncancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Fine needle aspiration cytology (FNAC) of adrenal masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Laparoscopic Versus Open Adrenalectomy for Adrenocortical Carcinoma: Surgical and Oncologic Outcome in 152 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Efficacy of Adjuvant Radiotherapy of the Tumor Bed on Local Recurrence of Adrenocortical Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Serendipitous adrenal masses: prevalence, significance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Comparative genomic hybridization analysis of adrenocortical tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Mortality rate of adrenocortical tumors in children under 15 years of age in Curitiba, Brazil

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Fine tuning of adrenocortical functions by locally produced growth factors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

High frequency of germline p53 mutations in childhood adrenocortical cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

31 March 2020

Adrenocortical carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenal masses: characterization with combined unenhanced and delayed enhanced CT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Imaging of adrenal masses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

How accurate is MR imaging in characterisation of adrenal masses: update of a long-term study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Transcription factor adrenal 4 binding protein as a marker of adrenocortical malignancy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Morphologic characteristics of benign and malignant adrenocortical tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

High diagnostic accuracy of adrenal core biopsy: results of the German and Austrian adrenal network multicenter trial in 220 consecutive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Surgical management, DNA content, and patient survival in adrenal cortical carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adjuvant and definitive radiotherapy for adrenocortical carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Recurrent or metastatic disease in select patients with adrenocortical carcinoma. Aggressive resection vs chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian National Registry for Adrenal Cortical Carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Emerging drugs for adrenocortical carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenal cortical carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Adrenocortical carcinoma: clinical, morphologic, and molecular characterization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Prognostic parameters of metastatic adrenocortical carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

Matrix metalloproteinase type 2 expression in malignant adrenocortical tumors: Diagnostic and prognostic significance in a series of 50 adrenocortical carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2010.235

p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies

31 March 2020

1 reference

12 December 2020

An eleven-year experience with adrenocortical carcinoma

1 reference

12 December 2020

Usefulness of VEGF, MMP-2, MMP-3 and TIMP-2 serum level evaluation in patients with adrenal tumours

1 reference

12 December 2020

Adrenocortical carcinoma: clinical and laboratory observations

1 reference

12 December 2020

Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors

1 reference

12 December 2020

Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors

1 reference

12 December 2020

Response to radiation therapy in adrenocortical carcinoma

1 reference

12 December 2020

Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16

1 reference

12 December 2020

Pathologic features of prognostic significance in adrenocortical carcinoma.

1 reference

12 December 2020

11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome

1 reference

12 December 2020

Role and cost-effectiveness of adrenal imaging and image-guided FNA cytology in the management of incidentally discovered adrenal tumours

1 reference

12 December 2020

Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas

1 reference

12 December 2020

The medical treatment of Cushing's syndrome

1 reference

12 December 2020

Mitotane for adrenocortical carcinoma treatment

1 reference

12 December 2020

Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors

1 reference

12 December 2020

Adrenal adenomas in a patient with Gardner's syndrome

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2010.235

1 reference

24 August 2017

1 reference